Skip to main content

Advertisement

Table 1 Patient information for US validation, patient information for SPECT/CT validation and retrospective US-guided injections

From: Feasibility of preoperative 125I seed-guided tumoural tracer injection using freehand SPECT for sentinel lymph node mapping in non-palpable breast cancer

Parameter Group 1, US validation (n = 10) (SD, range) Group 2, SPECT validation (n = 34) (SD, range) Group 3, retrospective US-guided injections (n = 21) (SD, range)
Patient age (years) 51 (8.4, 42 to 66) 61.3 (12.1, 26 to 89) 59 (10.6, 42 to 86)
Tumour size (mm) 11.5 (3.1, 9 to 20) 17.1 (13.8, 3 to 60) 18.4 (13.1, 8 to 55)
Tumour type DCIS (n = 3), IDC (n = 6), ILC (n = 1) DCIS (n = 12), LCIS (n = 1), IDC (n = 14), ILC (n = 4), unknown (n = 3) DCIS (n = 14), LCIS (n = 4), unknown (n = 3)
Number of 125I seeds 1 with 1 seed (30), with 2 seeds (4) 1
Location of 125I seeds 3 medial, 6 lateral, 1 central 7 medial, 22 lateral, 5 central 5 medial, 13 lateral, 3 central
Days after 125I seed implantation 30 (13, 12 to 56) 33.5 (23.3, 10 to 118) Not measured
125I seed depth by US (mm) 11.6 (6.4, 5 to 23) Not measured Not measured
125I seed depth by freehand SPECT (mm) 11.5 (6.6, 5 to 25) 15.3 (6.7, 8 to 35) Not measured
Difference in localisation or location (mm) Mean difference, 0.05 (2.4, −3.5 to 5)   
Absolute mean difference, 1.6 (1.6, 0 to 5) 10.9 (6.8, 0 to 29) (CT compared with SPECT) 9.7 (6.5, 2 to 30) (CT compared with SPECT)  
Irradical procedures 1/10 (focal irradical) 9/34 (focal irradical or irradical) 5/21 (focal irradical or irradical)
  1. DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; LCIS, lobular carcinoma in situ.